Kalif Eliyahu Sharon sold $3.6M of TEVA
Kalif Eliyahu Sharon (EVP, Chief Financial Officer) sold 106,563 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.10 ($3.63M total) on 2026-06-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental information about insider behavior but does not introduce new operating or financial fundamentals for TEVA.
Market read
A CFO open-market sale worth ~$3.63M is disclosed; 10b5-1 status suggests limited fundamental implications.
What to watch
Traders may over-weight insider sales; without accompanying guidance, litigation, or operational updates, the signal is mostly sentiment and positioning rather than a catalyst.
Background
The article is an SEC Form 4 insider transaction disclosure for TEVA, showing an officer sale executed under a Rule 10b5-1 plan.
Ticker impact
TEVA CFO Kalif Eliyahu Sharon sold 106,563 shares in an open-market transaction worth about $3.63M under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.
The filing is a primary SEC Form 4 disclosure, but the transaction is explicitly pre-arranged (10b5-1), which typically dampens market reaction versus discretionary selling.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on TEVA fundamentals.
Key entities
- issuerTEVA
TEVA Pharmaceutical Industries Ltd; subject of the insider transaction disclosure.
- insiderKalif Eliyahu Sharon
TEVA EVP and Chief Financial Officer who sold shares.
